Valion Bio (VBIO) Net Cash Flow (2021 - 2025)

Valion Bio has reported Net Cash Flow for 5 years, with the latest figure at $9.2 million in Q4 2025.

• On a quarterly basis, Net Cash Flow rose 6354.42% year-over-year to $9.2 million in Q4 2025; TTM through Dec 2025 was $10.6 million, a 863.96% increase from a year earlier, with the FY2025 full-year figure at $10.6 million, up 863.96% from the prior year.
• Net Cash Flow was $9.2 million for Q4 2025 at Valion Bio, up from $2.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $12.1 million in Q4 2021, with the low at -$2.8 million in Q4 2022.
• Average Net Cash Flow over 5 years is $577200.0, with a median of -$609500.0 recorded in 2021.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 396.85% in 2022, then surged 6354.42% in 2025.
• Over 5 years, Net Cash Flow stood at $12.1 million in 2021, then tumbled by 123.11% to -$2.8 million in 2022, then jumped by 36.71% to -$1.8 million in 2023, then surged by 91.71% to -$147000.0 in 2024, then soared by 6354.42% to $9.2 million in 2025.
• The last three Net Cash Flow figures came in at $9.2 million (Q4 2025), $2.3 million (Q3 2025), and $526000.0 (Q2 2025), per Business Quant data.